Switch theme
Sign up to access all valuation multiples
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others. It earns maximum revenue from European country.
2003
17
LTM Revenue $17.4M
LTM EBITDA $13.4M
$158M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bioventix has a last 12-month revenue of $17.4M and a last 12-month EBITDA of $13.4M.
In the most recent fiscal year, Bioventix achieved revenue of $17.5M and an EBITDA of $13.8M.
Bioventix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bioventix valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $16.5M | $17.5M | XXX | XXX | XXX |
| Gross Profit | $14.2M | $15.4M | XXX | XXX | XXX |
| Gross Margin | 86% | 88% | XXX | XXX | XXX |
| EBITDA | $13.2M | $13.8M | XXX | XXX | XXX |
| EBITDA Margin | 80% | 79% | XXX | XXX | XXX |
| Net Profit | $9.9M | $10.8M | XXX | XXX | XXX |
| Net Margin | 60% | 62% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Bioventix's stock price is GBP 25 (or $32).
Bioventix has current market cap of GBP 128M (or $165M), and EV of GBP 123M (or $158M).
See Bioventix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $158M | $165M | XXX | XXX | XXX | XXX | $1.95 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Bioventix has market cap of $165M and EV of $158M.
Bioventix's trades at 9.1x LTM EV/Revenue multiple, and 11.8x LTM EBITDA.
Analysts estimate Bioventix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Bioventix and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $158M | XXX | XXX | XXX |
| EV/Revenue | 9.1x | XXX | XXX | XXX |
| EV/EBITDA | 11.7x | XXX | XXX | XXX |
| P/E | 15.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 15.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBioventix's NTM/LTM revenue growth is 0%
Bioventix's revenue per employee for the last fiscal year averaged $1.0M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Bioventix's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Bioventix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Bioventix and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 78% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 77% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.0M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 15% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 15% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
| AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Proteomics International | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| Genomictree | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bioventix acquired XXX companies to date.
Last acquisition by Bioventix was XXXXXXXX, XXXXX XXXXX XXXXXX . Bioventix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Bioventix founded? | Bioventix was founded in 2003. |
| Where is Bioventix headquartered? | Bioventix is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Bioventix have? | As of today, Bioventix has 17 employees. |
| Who is the CEO of Bioventix? | Bioventix's CEO is Mr. Peter John Harrison. |
| Is Bioventix publicy listed? | Yes, Bioventix is a public company listed on LON. |
| What is the stock symbol of Bioventix? | Bioventix trades under BVXP ticker. |
| When did Bioventix go public? | Bioventix went public in 2014. |
| Who are competitors of Bioventix? | Similar companies to Bioventix include e.g. Zomedica, AnteoTech, Proteomics International, Biohit. |
| What is the current market cap of Bioventix? | Bioventix's current market cap is $165M |
| What is the current revenue of Bioventix? | Bioventix's last 12-month revenue is $17.4M. |
| What is the current EBITDA of Bioventix? | Bioventix's last 12-month EBITDA is $13.4M. |
| What is the current EV/Revenue multiple of Bioventix? | Current revenue multiple of Bioventix is 9.1x. |
| What is the current EV/EBITDA multiple of Bioventix? | Current EBITDA multiple of Bioventix is 11.8x. |
| What is the current revenue growth of Bioventix? | Bioventix revenue growth between 2023 and 2024 was 6%. |
| Is Bioventix profitable? | Yes, Bioventix is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
